Clinical trials: Stage II Skin Cancer
Breast Cancer
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00176488
- Testing
- epirubicin, vinorelbine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics
Breast Cancer
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT01105312
- Testing
- letrozole, panobinostat, RNA analysis
- Where
- 172 sites in United States
- Volunteers
- 28 people
- Sponsor
- Alliance for Clinical Trials in Oncology
HER2-positive Breast Cancer, Stage II Breast Cancer
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
This phase II trial studies how well giving lapatinib ditosylate together with trastuzumab, paclitaxel, and surgery works in treating patients with breast cancer.
- Conditions
- HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01688609
- Testing
- lapatinib ditosylate, paclitaxel, trastuzumab
- Where
- 3 sites in United States, Japan
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Male Breast Cancer, Stage II Breast Cancer
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer.
- Conditions
- Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01931709
- Testing
- fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Breast Cancer
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function.
- Trial name
- NCT00464646
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 36 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- NSABP Foundation Inc
Ovarian Carcinoma, Breast Cancer
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to…
- Trial name
- NCT00679783
- Testing
- AZD2281
- Where
- 6 sites in Canada
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Breast Cancer, Stage II Breast Cancer
MARGetuximab Or Trastuzumab (MARGOT)
The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- MARGOT (NCT04425018)
- Testing
- Paclitaxel, Pertuzumab, Margetuximab
- Where
- 14 sites in United States
- Volunteers
- 174 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast…
- Trial name
- NCT01194869
- Testing
- Sorafenib, Cisplatin, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Metastatic Melanoma
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called panobinostat.
- Trial name
- NCT00925132
- Testing
- Temozolomide, Decitabine, Panobinostat
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Breast Cancer
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your…
- Trial name
- NCT00121134
- Testing
- Bevacizumab, Cyclophosphamide, Methotrexate
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Harold J. Burstein, MD, PhD
Breast Cancer, Metastatic Breast Cancer
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
- Trial name
- NCT02658084
- Testing
- Vinorelbine, Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Melanoma
Fecal Microbiota Transplant (FMT) in Melanoma Patients
The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
- Trial name
- NCT03341143
- Testing
- Fecal Microbiota Transplant with Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zarour, Hassane, MD
HER2-negative Breast Cancer, Inflammatory Breast Cancer
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
This phase I/II trial studies the side effects and best dose of romidepsin when given together with paclitaxel albumin-stabilized nanoparticle formulation and to see how well they work in treating patients with metastatic…
- Conditions
- HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01938833
- Testing
- Romidepsin, Abraxane
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic Melanoma, Brain Metastases
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain.
- Trial name
- EBRAIN-MEL (NCT03898908)
- Testing
- encorafenib, binimetinib, Whole brain radiation therapy
- Where
- 21 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Breast Cancer, Hormone Receptor Positive Tumor
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.
- Trial name
- NCT03874325
- Testing
- Durvalumab, Anastrozole 1mg, Letrozole 2.5mg
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
This randomized phase II trial studies how well giving pembrolizumab with standard chemotherapy, tumor infiltrating lymphocytes (TIL), and aldesleukin works in treating patients with melanoma that has spread to other areas of the…
- Conditions
- Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02500576
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NRR (NCT00006110)
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Triple Negative Breast Cancer
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women. Metastatic disease including metastatic breast cancer unfortunately remains incurable.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01307891
- Testing
- Abraxane alone, Abraxane + Tigatuzumab
- Where
- 10 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.